The invention relates to artificial transcription factors comprising polydactyl zinc finger proteins targeting promoters of genes involved in maladapted wound healing in the eye. Such artificial transcription factors are useful for the treatment of fibrocontractive retinal disorders, such asepiretinal gliosis, proliferative vitreoretinopathy, proliferative diabetic retinopathy and epiretinal membrane, and for the treatment of fibroplasia associated with glaucoma surgery.本發明係關於人工轉錄因子,其包含以眼睛的不適應性傷口癒合中所涉及之基因之啟動子為目標之多指鋅指蛋白。該等人工轉錄因子適用於治療纖維收縮性視網膜病症,諸如視網膜神經膠質增生、增生性玻璃體視網膜病變、增生性糖尿病性視網膜病及視網膜前膜,且適用於治療與青光眼手術相關之纖維組織增生。
